Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rondoni

Showing results (151-160 of 173) with videos related to

Pageof 18
Sort By:
Haematologica|August 2, 2007
The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective studyMichele Baccarani, Daniela Cilloni, Michela Rondoni, et al.
Cell Biology and Toxicology|September 14, 2021
Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cellsAndrea Ghelli Luserna Di Rorà, Martina Ghetti, Lorenzo Ledda, et al.
Journal of Translational Medicine|November 26, 2024
Exploring the role of PARP1 inhibition in enhancing antibody-drug conjugate therapy for acute leukemias: insights from DNA damage response pathway interactionsAndrea Ghelli Luserna di Rorà, Mouna Jandoubi, Antonella Padella, et al.
Blood|February 15, 2007
Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemiaJelena V Jovanovic, Joannah Score, Katherine Waghorn, et al.
Journal of Cardiovascular Medicine (Hagerstown, Md.)|October 25, 2006
Day-to-day variability of electrocardiographic diagnosis of left ventricular hypertrophy in hypertensive patients. Influence of electrode placementFabio Angeli, Paolo Verdecchia, Enrica Angeli, et al.
International Journal of Hematology|November 27, 2008
Advanced mast cell disease: an Italian Hematological Multicenter experienceLivio Pagano, Caterina Giovanna Valentini, Morena Caira, et al.
British Journal of Haematology|October 4, 2005
Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patientsDomenico Russo, Michele Malagola, Antonio de Vivo, et al.
American Journal of Hematology|February 6, 2015
Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemiasLuana Fianchi, Livio Pagano, Alfonso Piciocchi, et al.
Blood Advances|October 25, 2024
Long-term real-world evidence of CPX-351 of high-risk patients with AML identified high rate of negative MRD and prolonged OSThomas Cluzeau, Fabio Guolo, Edmond Chiche, et al.
Future Oncology (London, England)|September 13, 2018
The Italian Mastocytosis Registry: 6-year experience from a hospital-based registrySerena Merante, Virginia V Ferretti, Chiara Elena, et al.
Pageof 18

Showing results (151-160 of 173) with videos related to

Sort By:
Pageof 18
Haematologica|August 2, 2007
The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective studyMichele Baccarani, Daniela Cilloni, Michela Rondoni, et al.
Cell Biology and Toxicology|September 14, 2021
Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cellsAndrea Ghelli Luserna Di Rorà, Martina Ghetti, Lorenzo Ledda, et al.
Journal of Translational Medicine|November 26, 2024
Exploring the role of PARP1 inhibition in enhancing antibody-drug conjugate therapy for acute leukemias: insights from DNA damage response pathway interactionsAndrea Ghelli Luserna di Rorà, Mouna Jandoubi, Antonella Padella, et al.
Blood|February 15, 2007
Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemiaJelena V Jovanovic, Joannah Score, Katherine Waghorn, et al.
Journal of Cardiovascular Medicine (Hagerstown, Md.)|October 25, 2006
Day-to-day variability of electrocardiographic diagnosis of left ventricular hypertrophy in hypertensive patients. Influence of electrode placementFabio Angeli, Paolo Verdecchia, Enrica Angeli, et al.
International Journal of Hematology|November 27, 2008
Advanced mast cell disease: an Italian Hematological Multicenter experienceLivio Pagano, Caterina Giovanna Valentini, Morena Caira, et al.
British Journal of Haematology|October 4, 2005
Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patientsDomenico Russo, Michele Malagola, Antonio de Vivo, et al.
American Journal of Hematology|February 6, 2015
Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemiasLuana Fianchi, Livio Pagano, Alfonso Piciocchi, et al.
Blood Advances|October 25, 2024
Long-term real-world evidence of CPX-351 of high-risk patients with AML identified high rate of negative MRD and prolonged OSThomas Cluzeau, Fabio Guolo, Edmond Chiche, et al.
Future Oncology (London, England)|September 13, 2018
The Italian Mastocytosis Registry: 6-year experience from a hospital-based registrySerena Merante, Virginia V Ferretti, Chiara Elena, et al.
Pageof 18